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y 21, 2013.he purpose of the study was to investigate whether fertility therapy might contribute to subsequent cardiovascular
disease.Background Fertility medications are used for 1% of births yet may also lead to endothelial injury with long-term adverse
consequences for the mother.Methods A population-based cohort analysis was performed of women who gave birth in Ontario, Canada, between July 1,
1993, and March 31, 2010, distinguishing those who did and did not receive fertility therapy in the 2 years before
delivery. Cox proportional models were derived to estimate hazard ratios with and without adjustment for baseline
characteristics. The primary outcome was a composite cardiovascular endpoint of death, nonfatal coronary
ischemia, stroke, transient ischemic attack, thromboembolism, or heart failure.Results Among 1,186,753 women who delivered during the study period, 6,979 gave birth after fertility therapy. After 9.7
years of median follow-up, women who delivered after fertility therapy had fewer cardiovascular events than controls
(103 vs. 117 events per 100,000 person-years), equivalent to an unadjusted hazard ratio of 0.96 (95% conﬁdence
interval: 0.72 to 1.29, p ¼ 0.79) and an adjusted hazard ratio of 0.55 (95% conﬁdence interval: 0.41 to 0.74,
p < 0.0001). An apparent relative lower risk was observed across all age and income groups. Women who received
fertility therapy also had lower risk-adjusted all-cause mortality, thromboembolic events, subsequent depression,
alcoholism, and self-harm (p < 0.01 for each).Conclusions Successful fertility therapy was not associated with an increased risk of cardiovascular disease later in life.
(J Am Coll Cardiol 2013;62:1704–12) ª 2013 by the American College of Cardiology FoundationInfertility affects approximately 1 in 8 reproductive-age
couples globally (1,2) and can lead to enormous personal
stress (3).General reproductive assistance improves the chance
of pregnancy through medications that stimulate ovulation
(4–6) and now represents approximately 1% of all infants
born annually in North America (1,2,7). Many industrialized
countries support fertility therapy under national health
insurance programs (8). In addition, some American states
andCanadian provinces guarantee access to affordable fertility
care (1,9) whereas others offer no such programs (8,10).arch Institute and Cardiovascular Division,
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013; revised manuscript received May 9, 2013,Fertility therapy focuses attention toward achieving
pregnancy rather than long-term health (4–7,11–13) Clin-
ical decision making, to an extreme degree, prioritizes
a successful pregnancy (14), yet unintended toxicity can
occur. One concern is that fertility therapy might lead to
downstream cardiovascular events due to increased risks of
maternal metabolic syndromes (e.g., gestational diabetes
mellitus and hypertension), direct endothelial dysfunction,
and prothrombotic effects from ovarian hyperstimulationSee page 1713with hyperestrogenemia (9,15–27). Nevertheless, long-term
data are lacking on the health effects associated with fertility
therapy for women who have a successful pregnancy, in part
because of a lack of uniform reporting of adverse outcomes
after fertility therapy (28,29) and legislation sometimes
prohibiting health data linkage (30).
The potential association between fertility therapy and
subsequent cardiovascular disease is increasingly relevant
given societal trends for women to delay pregnancy until
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1705older age, and with a higher likelihood of baseline heart
disease (31–33). We questioned whether fertility therapy
might contribute to increased cardiovascular events after
successful pregnancy. The goal of the GRAVID (General
Reproductive Assistance and Vascular Illness Downstream)
study was to assess the long-term risk of premature cardio-
vascular disease for women after successful fertility drug
treatment.Methods
Study design and participants. We conducted a pop-
ulation-based cohort analysis of all women age 15 to
55 years who gave birth in Ontario, Canada, between July 1,
1993, and March 31, 2010. During this time, patients were
identiﬁed through the Ontario Health Insurance Plan, which
covered prenatal care as well as hospital and postnatal care.
We identiﬁed women through linked healthcare databases
utilizing obstetrical delivery of a liveborn or stillborn infant
after 20 weeks’ gestation (hospital database main patient
service code 51). For each woman, the ﬁrst delivery during the
study periodwas selected for inclusion so that patients counted
only once in analyses to avoid statistical artifacts from clus-
tered observations. Women with spontaneous miscarriages,
therapeutic abortions, or home births were not included. We
also excluded women who were not residents of Ontario and
those who lacked a valid health-card identiﬁer.
Deﬁnition of fertility therapy. We used computerized
searchmethods to screen for the use of fertility therapy during
the 2 years (730 days) before the date of delivery for each
woman (estimated gestational length of 270 days plus
460 days). We selected in advance a 2-year screening window
to be inclusive for women who may have received several
courses of fertility therapy before a successful pregnancy.
Women were classiﬁed dichotomously as having received or
not received fertility therapy according to whether they had
a claim for reproductive treatment monitoring of iatrogenic
ovulation (Ontario Health Insurance Plan code G334)
according to the intention-to-treat approach. If>1 claim was
present during the period, the date of the ﬁrst claim was
selected for primary analysis. Subsequently, patients who
received fertility therapywere classiﬁed as having 1 or repeated
claims for reproductive treatment monitoring to explore
potential dose-response relationships.
We focused on ovulation monitoring because the standard
of care generally involved adjuvant fertility therapy (4–7).
Moreover, the Ontario Health Insurance Plan code was
consistent during the entire accrual interval and identiﬁed
women participating in intrauterine insemination, in vitro
fertilization, and other forms of medically stimulated ovula-
tion (12). The Ontario Drug Beneﬁt Program database could
not identify speciﬁc fertility medication because Ontario did
not provide single-payer universal insurance coverage for
fertility medications (10). Therefore, our study examined the
physician’s monitoring of fertility therapy but not the speciﬁc
medications, doses, or strategies for the individual patient.Patient characteristics. We col-
lected baseline data on demo-
graphic and clinical factors from
the Canadian Institute for Health
Information hospital and outpa-
tient databases during the 2 years
before delivery. These databases,
which also served as the source for
identifying follow-up outcomes,
admissions, and procedures, have high reported completeness
(>99%) and diagnostic accuracy (>95%) in this setting
(34,35). The hospital database contained the patient’s age and
sex, date of admission, and diagnoses coded using the Inter-
national Classiﬁcation of Diseases (ICD [as many as 16 diag-
noses in ICD-9 and as many as 25 diagnoses in ICD-10]).
Because some conditions were primarily diagnosed on an
outpatientbasis (e.g., hypertension),wealso used the outpatient
database to identify additional diagnoses for the 2 years before
the index delivery. Demographic and health care utilization
covariates were assessed during the half year before conception
to identify additional determinants of health. Information
about the patient’s home location (urban versus rural) and
estimated income category was deﬁned using Canadian census
data through home postal code information. Obstetrical char-
acteristics and outcomes during the index delivery were also
collected. Information about parity, neonatal outcomes, labo-
ratory results, and prescription medications were not available.
Outcome deﬁnitions. We identiﬁed outcomes using the
Canadian Institute for Health Information hospital data-
base. Our primary outcome was the composite of death
or hospitalization for a major adverse cardiovascular event;
namely, nonfatal coronary ischemia, stroke, transient
ischemic attack, thromboembolism, or heart failure. We
used ICD-9 codes to identify study outcomes before March
31, 2002, and ICD-10 codes after April 1, 2002, to account
for the changes in coding over time. Potential mediators of
fertility treatment effects were explored along a plausible
causal pathway. In particular, we considered differential
effects in women with and without multiple gestations,
ovarian hyperstimulation syndrome, and gestational meta-
bolic disorders.
We conducted secondary analyses to examine additional
events using inpatient and outpatient databases. These included
individual components of the primary outcome as well as
processes of caremeasures (e.g., coronary revascularization).We
also analyzed for the emergence of 3 cardiovascular risk factors
(hypertension, diabetes, and hyperlipidemia) as a supplement
but not substitute for our primary outcome. For these secondary
analyses we excluded patients with any history of prior cardio-
vascular disease, hypertension, diabetes (including gestational
diabetes), and hyperlipidemia to provide a stringent assess-
ment of the development of cardiovascular risk factors.
We further evaluated noncardiovascular outcomes poten-
tially associated with fertility therapy including hormonally
mediated cancers (e.g., breast cancer, ovarian cancer),
depression, and self-harm. We also selected 5 common
Table 1 Baseline Characteristics
Characteristic
Fertility Therapy Absent
(n ¼ 1,179,774)
Fertility Therapy Present
(n ¼ 6,979) p Value
Age, yrs 29 (25–33) 34 (31–36) <0.001
Age <35 yrs 1,001,177 (85%) 4,064 (58%) <0.001
Urban residence 1,037,554 (88%) 6,637 (95%) <0.001
Income quintile 1 260,872 (22%) 766 (11%) <0.001
2 242,921 (21%) 1,144 (16%)
3 239,930 (20%) 1,465 (21%)
4 238,255 (20%) 1,799 (26%)
5 191,118 (16%) 1,799 (26%)
Unknown 6,678 (1%) 6 (<1%)
Physician visits prior 6 months 12 (6–22) 49 (31–75) <0.001
No. of antenatal visits 11 (9–13) 12 (10–13) <0.001
No. obstetrician antenatal visits 8 (0–11) 11 (9–13) <0.001
Weekday delivery 833,357 (71%) 4,911 (70%) 0.6
Charlson index 0 1,170,923 (99%) 6,936 (99%) 0.17
1 8,851 (1%) 43 (1%)
Prior operative vaginal delivery 50,843 (4%) 37 (0.5%) <0.001
Prior Cesarean delivery 12,221 (1%) 10 (0.1%) <0.001
Prior multiple gestation 686 (0.1%) 13 (0.2%) <0.001
Prior abnormal pregnancy 85,476 (7%) 378 (5%) <0.001
Endometriosis 2,403 (0.2%) 86 (1%) <0.001
Prior ovarian hyperstimulation 243 (0.1%) 40 (4%) <0.01
Sexually transmitted infection 25,827 (2.2%) 84 (1.2%) <0.001
Pelvic inﬂammatory disease 4,565 (0.4%) 79 (1%) <0.001
Cervix disorders* 236 (0%) 5 (0%) 0.6
Other genital tract disorders 5,300 (0.4%) 75 (1%) <0.001
Renal disease 628 (0.1%) 5 (0%) 0.7
Liver disease 344 (0%) 0 (0%) 0.2
History of neoplasm 5,094 (0.4%) 71 (1.0%) <0.001
History of major trauma 291 (0%) 5 (0%) 0.8
Alcoholism 6,184 (2.5%) 11 (0.2%) <0.001
Depression 42,907 (3.6%) 234 (3.4%) 0.2
Self-harm 1,117 (0.1%) 5 (0%) 0.03
Ischemic heart disease 80 (<0.01%) 0 (0%) 0.5
Cardiomyopathy 51 (<0.01%) 0 (0%) 0.5
Cerebrovascular diseases 174 (<0.01%) 0 (0%) 0.3
Thromboembolic disease 89 (<0.01%) 0 (0%) 0.5
Pulmonary circulation disease 243 (<0.01%) 5 (0%) 0.7
Peripheral artery disease 138 (<0.01%) 5 (0%) 0.2
Cardiovascular risk factors
Hypertension 29,083 (2.5%) 217 (3.1%) <0.001
Hyperlipidemia 29,014 (2.5%) 263 (3.8%) <0.001
Diabetes mellitus, including prior GDM 17,600 (1.5%) 153 (2.2%) <0.001
Obstetrical characteristics
Length of stay, days 2 (2–3) 3 (2–4) <0.001
Multiple gestation, uncomplicated 9,701 (1%) 315 (4.5%) <0.001
Multiple gestation, complicated 8,341 (1%) 315 (4.5%)
Continued on the next page
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1706illnesses to check for the lack of a difference where no
difference would be expected (e.g., pneumonia, melanoma,
lung cancer, nephrolithiasis, motor vehicle trauma). Finally,
we explored the incidence of alcoholism and sexually trans-
mitted infections to assess additional determinants of health.
Statistical analysis. Baseline demographic and clinical
characteristics were compared between groups using the
chi-square test for categorical variables and the t test orKruskal-Wallis test for continuous variables. The association
between fertility therapy and short-term pregnancy outcomes
was assessed using the chi-square test and logistic regression.
Probability curves and event rates for the primary and
secondary outcomes followed theKaplan-Meier approach.We
followed up all patients until they had an outcome event or
reached the end of follow-up (March 31, 2011), whichever
came ﬁrst. Survival timewas estimated according to the date of
Table 1 Continued
Characteristic
Fertility Therapy Absent
(n ¼ 1,179,774)
Fertility Therapy Present
(n ¼ 6,979) p Value
Obstetrical procedures
Cesarean delivery 314,960 (27%) 2,853 (41%) <0.001
Operative vaginal delivery 589,572 (50%) 2,527 (36%) <0.001
Other procedures assisting labor 258,341 (22%) 1,424 (20%) 0.003
Malposition and malpresentation of fetus 66,128 (6%) 409 (6%) 0.355
Disproportion 37,988 (3.2%) 189 (2.7%) 0.02
Abnormality of pelvic organs 57,725 (5%) 197 (3%) <0.001
Abnormality of the fetus 3,205 (0.3%) 26 (0.4%) 0.107
Suspected fetal problemsy 142,263 (12%) 637 (9%) <0.001
Misc. amniotic ﬂuid and cavity abnormalitiesz 83,899 (7%) 380 (5%) <0.001
Serious obstetrical complicationsx 205,680 (17%) 702 (10%) <0.001
Values are median (interquartile range) or n (%). Baseline characteristics were ascertained for 2 years before the date of index delivery. *Including incompetent
cervix. yIncluding intrauterine growth restriction, intrauterine death, placental infarct. zIncluding polyhydramnios, oligohydramnios, premature rupture of
membranes, infection of amniotic cavity. xIncluding obstructed labor, umbilical cord complications, major perineal trauma, postpartum hemorrhage, and
obstetric shock.
GDM ¼ gestational diabetes mellitus; Misc. ¼ miscellaneous.
JACC Vol. 62, No. 18, 2013 Udell et al.
October 29, 2013:1704–12 Fertility Therapy and Cardiovascular Risk
1707the outcome, with data censored at the time of the last available
information for patients who had no event. We used propor-
tional hazardsmodels to estimate a hazard ratio (HR) and 95%
conﬁdence interval (CI) for the study outcomes comparing
women with and without fertility therapy. The assumption of
proportional hazards was conﬁrmed by Schoenfeld’s test.
Multivariable analyses were based on regression models
that adjusted for maternal age, calendar year, multiple
gestations, home location, neighborhood income, prior
physician visits, antenatal visits to an obstetrician, history of
cardiovascular risk factors, smoking, obesity, other baseline
comorbidities, obstetrical characteristics, and length of
stay. We constructed all multivariable models maintaining
a ratio of 1:10 between outcomes and predictors. Given
that past research has indicated an inverse association
between income and fertility (36), we deliberately explored
the consistency of ﬁndings across socioeconomic subgroups
by examining interaction terms for fertility therapy with age
or income. In addition, we explored whether a dose-response
relationship was present by analyzing results according to
whether patients received 1 or repeated fertility treatments.
All p values were 2-sided and calculated with the Wald chi-
square test with a threshold <0.05 considered signiﬁcant
using SAS for UNIX (version 8.02; SAS Institute, Cary,
North Carolina).
Descriptive characteristics with cell sizes containing
between 1 and 5 patients were censored according to local and
provincial privacy reporting regulations. The ethics review
board of Sunnybrook Health Sciences Centre approved the
study. The funding agencies had no role in the design, anal-
ysis, interpretation of the data, nor in the preparation or
decision to submit the manuscript for publication.Results
Characteristics of patients. Atotal of 1,186,753womenhad
an obstetrical delivery during the study interval (Table 1). Themean age was 29  5 years and 6,979 (0.6%) had received
fertility therapy in the 2 years before delivery. Among women
with an obstetrical delivery, the use of fertility therapy increased
signiﬁcantly over time from approximately 1 in 400 to ap-
proximately 1 in 80 during the 17-year study interval. Women
with a delivery after fertility therapy were more likely to be
older, living in the highest income quintile, and accumu-
lated a greater number of pre-natal visits compared with
women delivering without fertility therapy. At baseline, we
observed a higher prevalence of 4 cardiovascular risk factors
(older age, hypertension, hyperlipidemia, and diabetes)
among women who used fertility therapy (Table 1). In
contrast, we observed no signiﬁcant differences in the rate
of 6 indicators of established cardiovascular disease between
the 2 groups. As expected, women who gave birth after
fertility therapy more commonly had a history of pelvic
inﬂammatory disease, endometriosis, and cancer. Women
who gave birth after fertility therapy were also more likely to
carry multiple gestations, deliver by Cesarean section, and
have longer lengths of hospital stay.
Short-term outcomes. Womenwho gave birth after fertility
therapy had an increased risk of having maternal metabolic
syndromes (Table 2) including gestational diabetes (adjusted
odds ratio [OR]: 1.29, 95% CI: 1.17 to 1.41, p < 0.0001),
serious placental complications (adjusted OR: 1.16, 95%
CI: 1.04 to 1.29, p ¼ 0.01), and pre-eclampsia (adjusted
OR: 1.10, 95% CI: 1.01 to 1.20, p ¼ 0.02). Fertility therapy
was also associated with developing pre-term threatened
labor (adjusted OR: 1.41, 95% CI: 1.31 to 1.52, p< 0.0001),
ovarian hyperstimulation syndrome (adjusted OR: 3.29, 95%
CI: 2.37 to 4.57, p < 0.0001), and urinary tract infections
(adjusted OR: 1.22, 95% CI: 1.08 to 1.40, p ¼ 0.006).
In contrast, the 2 groups had similar rates of gestational
hypertension, hyperemesis gravidarum, renal complications,
liver complications, and puerperium septicemia.
Long-term cardiovascular outcomes. During a median
follow-up of 9.7 years (interquartile range: 4.6 to 14.0) a total
Table 2 Short-Term Pregnancy Outcomes
Peripartum Events
Fertility Therapy Absent
(n ¼ 1,179,774)
Fertility Therapy Present
(n ¼ 6,979) p Value
Gestational hypertension* 46,919 (4%) 270 (4%) 0.6
Gestational diabetes 34,176 (3%) 536 (8%) <0.001
Pre-eclampsia or eclampsiay 39,812 (3%) 480 (7%) <0.001
Serious placental complicationsz 37,314 (3%) 391 (6%) <0.001
Abnormal pregnancy 1,089 (0.1%) 23 (0.3%) <0.001
Excessive vomiting 10,416 (0.9%) 48 (0.7%) 0.08
Pre-term or threatened labor 98,019 (8%) 1,147 (16%) <0.001
Late pregnancy 127,212 (11%) 576 (8%) <0.001
Ovarian hyperstimulation syndrome 385 (0%) 51 (1%) <0.001
Peripheral edema or excessive weight gain 1,998 (0.2%) 14 (0.2%) 0.5
Renal disorders in pregnancy 1,069 (0.1%) 5 (0%) 0.2
Liver disorders in pregnancy 448 (0%) 5 (0%) 0.3
Septicemia or genitourinary tract infections 25,341 (2%) 218 (3%) <0.001
Other puerperium complicationsx 14,541 (1%) 136 (2%) <0.001
Values are n (%). *Including benign essential hypertension complicating pregnancy, hypertension from renal disease complicating pregnancy, other pre-existing
hypertension complicating pregnancy, transient hypertension in pregnancy, unspeciﬁed hypertension complicating pregnancy. yIncluding mild or unspeciﬁed
pre-eclampsia (with either albuminuria or edema or both), severe pre-eclampsia, eclampsia, pre-eclampsia, or eclampsia superimposed on pre-existing
hypertension. zIncluding antepartum hemorrhage, placenta previa, placental abruption. xIncluding puerperal infections.
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1708of 12,774 primary outcome events were observed, of which 44
occurred among women after fertility therapy and 12,730
occurred among women who delivered without fertility
therapy. Women who gave birth after fertility therapy had
fewer primary outcome events than women who delivered
without fertility therapy (103 vs. 117 events per 100,000
person-years; unadjusted HR: 0.96, 95% CI: 0.72 to 1.29,
p¼ 0.79) (Fig. 1). The observed decreased risk associated with
fertility therapy was further accentuated after adjustment for
differences in age, year of delivery, demographic factors, base-
line medical history, baseline obstetrical characteristics, and
short-term complications of pregnancy (adjusted HR: 0.55,
95% CI: 0.41 to 0.74, p< 0.0001) (Table 3, Online Table 1).
Subgroup analysis conﬁned to women 30 years of age
yielded similar results (unadjusted HR: 0.78, 95% CI: 0.56 to
1.08, p ¼ 0.14; adjusted HR: 0.56, 95% CI: 0.40 to 0.78,
p ¼ 0.0007).
Individual components of the primary outcome occurred
infrequently, yet fertility therapy was associated with lower
rates of both mortality (adjusted HR: 0.50, 95% CI: 0.31 to
0.80, p ¼ 0.004) and thromboembolic events (adjusted HR:
0.45, 95% CI: 0.21 to 0.94, p ¼ 0.03). We observed an
increase in crude rates of coronary ischemic events, heart
failure, and cerebrovascular events among women who gave
birth after fertility therapy, yet each association was not
signiﬁcant after multivariable adjustment (adjusted HR for
coronary ischemic events: 0.56, 95% CI: 0.25 to 1.25,
p ¼ 0.15; adjusted HR for heart failure: 0.60, 95% CI: 0.30
to 1.22, p ¼ 0.16; adjusted HR for cerebrovascular events:
1.14, 95% CI: 0.54 to 2.44, p ¼ 0.73).
We observed no increased cardiovascular risk associated
with fertility therapy in subgroups stratiﬁed by age (Online
Fig. 1), presence of polycystic ovarian syndrome, method
of assisted reproduction, number of cardiovascular risk
factors, number of gestations, or development of ovarianhyperstimulation syndrome (p for interaction > 0.2 for all).
As expected, the development of gestational diabetes was
associated with an increased risk of long-term cardiovascular
events (adjusted HR: 1.27, 95% CI: 1.16 to 1.38; p <
0.0001), as was the development of gestational hypertension,
pre-eclampsia, or eclampsia (adjusted HR: 1.46, 95% CI:
1.38 to 1.55; p < 0.0001), independent of fertility therapy
and other baseline characteristics. The lower risk of
cardiovascular events associated with fertility therapy was
consistent across all income groups (p for interaction ¼ 0.7)
(Online Fig. 2).
Emergence of cardiovascular risk factors. In an analysis
restricted to patients without prevalent cardiovascular
disease, hypertension, diabetes (including gestational dia-
betes), or hyperlipidemia at baseline, incidence rates
of cardiovascular risk factor development occurred more
frequently among women after fertility therapy than
controls (5.91 vs. 3.83 events per 100 person-years; unad-
justed HR: 1.53, 95% CI: 1.46 to 1.60, p < 0.0001)
(Table 3). After multivariable adjustment, however, we
observed less risk of emergent hypertension, diabetes,
or hyperlipidemia after fertility therapy (adjusted HR: 0.86,
95% CI: 0.82 to 0.90, p < 0.0001; Online Table 1). In
addition, we observed no signiﬁcant difference in the risk of
subsequent coronary revascularization with and without
fertility therapy (adjusted HR: 1.18, 95% CI: 0.55 to 2.51,
p ¼ 0.67).
Other medical and mental health outcomes. After
adjustment for age and other baseline characteristic differ-
ences between the 2 groups, we observed no signiﬁcant
increased risk associated with breast cancer development
(adjusted HR: 0.74, 95% CI: 0.45 to 1.19; p ¼ 0.2)
or ovarian malignancies (adjusted HR: 1.12, 95% CI:
0.41 to 3.05; p ¼ 0.8) among women who gave birth after
fertility therapy. Fertility therapy was not associated with
Figure 1
Incidence of Primary Outcome With or Without
Fertility Therapy
Kaplan-Meier cumulative incidence curves for the primary outcome (composite
cardiovascular endpoint of death, nonfatal coronary ischemia, stroke, transient
ischemic attack, thromboembolism, and heart failure) among women giving birth
according to fertility therapy status: absent (red line) or present (blue line).
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1709a signiﬁcant increase or decrease in risk of pneumonia,
melanoma, lung cancer, or nephrolithiasis (Table 4 , Online
Table 2).
Women who gave birth after fertility therapy experi-
enced fewer adverse mental health events compared to
controls (Table 4). Speciﬁcally, the use of fertility therapy
was associated with one-third of the rate of subsequent
depression and one-seventh the rate of subsequent self-
harm (p < 0.001 for both). In addition, fertility therapy
was associated with a decrease in other potential adverseTable 3 Long-Term Cardiovascular Outcomes
Outcome
Event Rate by Fert
(per 100,000 Per
Absent
Major cardiovascular events (n ¼ 1,179,774)
Death or cardiovascular event 117.0
Death 53.8
Cardiac ischemia 16.7
Heart failure 14.6
Venothromboembolic events 28.0
Cerebrovascular events 8.5
Emergent cardiovascular risk factorsy (n ¼ 1,108,322)
Any hypertension, diabetes, or hyperlipidemia 3,831
Hypertension 1,985
Diabetes mellitus 1,046
Hyperlipidemia 1,393
Hazard ratios represent the risk among women with fertility compared with women without fertility thera
prior physician visits, antenatal visits to an obstetrician, prior medical history (including hypertension,
infertility, endometriosis, polycystic ovarian syndrome, sexually transmitted infections, pelvic inﬂamma
delivery, prior Cesarean delivery, prior multiple gestation, and prior abnormal pregnancy), length of sta
complicated gestations, Cesarean delivery, operative delivery, assisted labor procedures, disproportion, ab
and other serious obstetrical complications). yAnalyses restricted to patients without history of prior ca
baseline. zRisk adjusted for all variables listed above except hypertension, diabetes (including gestation
CI ¼ conﬁdence interval.health behavior-related outcomes including about one-half
the rate of incident alcoholism and two-thirds the rate of
sexually transmitted infections among women with no prior
history before delivery (p < 0.0001 for both). All observed
associations persisted after adjustment for baseline char-
acteristics, with or without further adjustment for obstet-
rical characteristics.
Discussion
Overall, we observed a 5-fold increase in the use of fertility
therapy over the last 2 decades, particularly among older
women. The use of fertility therapy was associated with an
increase in several short-term pregnancy complications, yet
women who delivered after fertility therapy had about half
the risk of long-term death or major adverse cardiovascular
events compared to controls. The decreased risk of long-
term adverse events associated with fertility therapy was
consistent across age and socioeconomic groups. Our anal-
ysis focused on women who achieved a pregnancy of at least
20 weeks’ gestation, and we cannot comment on the
cardiovascular risk among those women who did not achieve
pregnancy or had a loss before delivery.
Our ﬁndings contrast with other epidemiologic and
clinical research that suggested cardiometabolic monitoring
after fertility therapy to detect cardiothoracic disease
(24,25,27,29,37–40). A recent study from the Netherlands
reported an in vitro fertilization–associated maternal
mortality rate of 42.5 per 100,000 live births, which is 4 times
higher than the baseline. In the United Kingdom, 25% of
maternal deaths associated with fertility therapy were
considered directly related to development of ovarian
hyperstimulation syndrome (38). Other studies, however,ility Therapy
son-Years) Hazard Ratio (95% CI)
Present Unadjusted Adjusted*
(n ¼ 6,979)
102.6 0.96 (0.72–1.29) 0.55 (0.41–0.74)
41.9 0.94 (0.59–1.50) 0.50 (0.31–0.80)
14.0 1.23 (0.55–2.74) 0.56 (0.25–1.25)
18.6 1.13 (0.56–2.26) 0.60 (0.30–1.22)
16.3 0.54 (0.26–1.13) 0.45 (0.21–0.94)
16.3 2.14 (1.02–4.50) 1.14 (0.54–2.44)
(n ¼ 6,394) z
5,907 1.53 (1.46–1.60) 0.86 (0.82–0.90)
2,945 1.52 (1.43–1.61) 0.88 (0.83–0.94)
1,816 1.68 (1.56–1.81) 0.93 (0.86–1.00)
2,094 1.63 (1.52–1.75) 0.85 (0.79–0.91)
py (reference). *Risk adjusted for age, calendar year, geographic residence, neighborhood income,
hyperlipidemia, diabetes mellitus [including gestational diabetes], neoplasm, alcoholism, female
tory disease, other genital tract disorders, prior ovarian hyperstimulation syndrome, prior vaginal
y and obstetrical characteristics for the index delivery (including number of gestations, number of
normality of pelvic organs, suspected fetal problems, amniotic ﬂuid and uterine cavity abnormalities,
rdiovascular disease, hypertension, diabetes (including gestational diabetes), or hyperlipidemia at
al diabetes), and hyperlipidemia.
Table 4 Long-Term Risk of Other Serious Events
Outcome
Events Rate by Fertility Therapy
(per 100,000 Person-Years) Hazard Ratio (95% CI)
Absent
(n ¼ 1,179,774)
Present
(n ¼ 6,979) Unadjusted Adjusted*
Malignancies
Breast 33.1 39.6 1.42 (0.88–2.28) 0.74 (0.45–1.19)
Ovarian 5.6 9.3 2.04 (0.76–5.46) 1.12 (0.41–3.05)
Melanoma 0.9 2.3 2.85 (0.40–20.5) 1.80 (0.24–13.7)
Pneumonia 49.5 49.0 1.00 (0.65–1.54) 0.73 (0.47–1.13)
Nephrolithiasis 40.7 32.6 0.75 (0.45–1.27) 0.71 (0.42–1.21)
Alcoholism 164.7 84.2 0.53 (0.38–0.73) 0.48 (0.35–0.67)
Sexually transmitted infections 538.2 351.0 0.63 (0.54–0.74) 0.64 (0.55–0.76)
Motor vehicle collisions 37.1 16.3 0.44 (0.21–0.92) 0.51 (0.24–1.07)
Depression 76.0 26.0 0.32 (0.18–0.58) 0.33 (0.18–0.59)
Self-harm 48.1 4.7 0.09 (0.02–0.35) 0.15 (0.04–0.62)
Values are %. Hazard ratios represent the risk among women with fertility compared with women without fertility therapy (reference). *Risk adjusted for age, calendar year, geographic residence,
neighborhood income, prior physician visits, antenatal visits to an obstetrician, prior medical history (including hypertension, hyperlipidemia, diabetes mellitus [including gestational diabetes], neoplasm,
alcoholism, female infertility, endometriosis, polycystic ovarian syndrome, sexually transmitted infections, pelvic inﬂammatory disease, other genital tract disorders, prior ovarian hyperstimulation syndrome,
prior vaginal delivery, prior Cesarean delivery, prior multiple gestation, and prior abnormal pregnancy), length of stay and obstetrical characteristics for the index delivery (including number of gestations,
number of complicated gestations, Cesarean delivery, operative delivery, assisted labor procedures, disproportion, abnormality of pelvic organs, suspected fetal problems, amniotic ﬂuid and uterine cavity
abnormalities, and other serious obstetrical complications).
CI ¼ conﬁdence interval.
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fertility therapy. The present study’s substantially longer
duration of follow-up may partly explain the difference
in observed risk associated with fertility therapy in contrast
to prior reports (17,24,27,37–39,41). Most prior studies
report no large association between fertility therapy and
increased long-term risk of estrogen-related malignancies,
consistent with our observations (42–44).
One interpretation of our ﬁndings is a widespread selec-
tion bias associated with fertility therapy that might offset
a potential detrimental biologic consequence. That is,
perhaps women who have fertility challenges and seek
fertility therapy are prone toward healthier behavior after
successful obstetrical delivery (45,46), a pattern that extends
across diverse age and income groups. An alternative
hypothesis is that fertility therapy offers an unknown
pleiotropic biologic protective mechanism (47,48). A third
possibility is that women with distinctly adverse lifestyles do
not generally seek fertility treatment (49). The full expla-
nation is unclear and requires more research on these
determinants of health.
Study limitations. Our ﬁndings should be interpreted with
caution. Population-based cohort studies have limitations
due to potentially missing clinical data yet remain powerful
designs to examine adverse outcomes otherwise missed in
randomized trials. We focused on women who achieved
a ﬁrst pregnancy of at least 20 weeks’ gestation, and that may
have overlooked adverse effects among women who did not
achieve pregnancy, had a gestation shorter than 20 weeks, or
experienced adverse subsequent deliveries. The utilization of
ovulation monitoring to estimate fertility therapy was an
efﬁcient method to test the core hypothesis although we
could not directly ascertain speciﬁc medication or dose. As
a result, our approach provided a sensitive but not speciﬁcmethod of determining the safety of fertility therapy. Potential
unmeasured confounders such as education, functional status,
body mass index, smoking history, glycemic control, and
parity were not fully accounted. The effects of psychological
stress, marital status, sexual orientation, or cultural motivators
were also not available.
Further re-evaluation of patients for emergence of
cardiovascular events at a later age will be important given
the relative young age and brief duration of follow-up in this
report. The major difference between unadjusted and
adjusted relative risk estimates for the primary results was
mostly explained by the higher age, income status, number
of prenatal visits, and cardiovascular risk factor proﬁle
among women who received fertility therapy. The con-
trasting unadjusted and adjusted results regarding the risk
of emergent cardiovascular risk factors among the subset of
women at baseline without prevalent cardiovascular disease,
hypertension, diabetes, or hyperlipidemia was primarily
explained by adjustment for imbalances between groups in
age and year of entry into the study.
Conclusions
This is the ﬁrst large population-based study to assess the
long-term risk of cardiovascular disease after fertility
therapy. Fertility treatment has become popular over the past
3 decades, leading to a growing need to ascertain its long-
term safety (29,37,38). A better understanding of the
long-term risks associated with fertility therapy might help
inform decision-making around reproductive technology
and motivate cardiovascular risk reduction. The current
ﬁndings provide some reassurance that fertility therapy does
not appear to increase long-term risk of cardiovascular events
after successful pregnancy.
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